IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2190 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Article in PDF (22 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   Article Figures

 Article Access Statistics
    Viewed1322    
    Printed43    
    Emailed0    
    PDF Downloaded229    
    Comments [Add]    

Recommend this journal

 


 
EDITORIAL
Year : 2008  |  Volume : 40  |  Issue : 7  |  Page : 3
 

About our Guest Editor



Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21369411

Rights and PermissionsRights and Permissions



How to cite this article:
. About our Guest Editor. Indian J Pharmacol 2008;40, Suppl S1:3

How to cite this URL:
. About our Guest Editor. Indian J Pharmacol [serial online] 2008 [cited 2019 Sep 22];40, Suppl S1:3. Available from: http://www.ijp-online.com/text.asp?2008/40/7/3/40234


Dr. Pipasha Biswas is currently Principal Consultant & Director of Symogen Ltd, UK, which is her own company which undertakes consultancy work and projects on all aspects of Pharmacovigilance & Pharmacoepidemiology. She has been involved in pharmacovigilance for the last 12 years in Europe, USA and India. She has worked in a number of MNCs in Pharmacovigilance as Executive Director and Lead for Safety Signal detection at Global Drug Safety at Amgen Inc based in California, where she lead the safety signal detection team in global safety. In the UK, she worked as Director, Safety Evaluation and Risk Management, Global Clinical Safety and Pharmacovigilance at GSK, where she was the lead physician responsible for Respiratory and Antiinflammatory therapeutic area. Prior to working at GSK, London, she was EU Senior Pharmacovigilance Physician at the European Office of Global Safety Surveillance and Epidemiology at Wyeth Europa, based in the UK. Before moving to the pharmaceutical industry, she was Clinical Research Fellow at the Drug Safety Research Unit, based in Southampton, where she conducted large studies in post marketing surveillance.

She also has considerable experience in Clinical Research and Clinical Drug Development, having worked at the Department of Vascular Medicine, King's College of Medicine & Dentistry, where she was responsible for conducting clinical trials in Deep Vein Thrombosis patients from phase II to III.

She qualified in Medicine from VSS Medical College, University of Sambalpur, India and then trained in Internal Medicine and did her post graduation in Pharmaceutical Medicine, from University of Surrey, UK. She then specialized in Pharmacovigilance & Pharmacoepidemiology from London School of Hygiene and Tropical Medicine, London and then did her DM in Pharmacoepidemiology from University of Southampton, UK.

She is the Member of British Association of Regulatory and Quality Assurance (BARQA), International Society of Pharmacovigilance (ISOP) and International Society of Pharmacoepidemiology (ISPE). She is also Affiliate Member of the Faculty of Pharmacuetical Medicine, of The Royal College of Physicians, London, UK. She has been recently conferred with the Fellowship of The Royal Society of Medicine, UK.


    Figures

  [Figure - 1]



 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow